Published Date:2023-05-31 Original Link:https://www.onenessbio.com/en/news_detail222_3.htm No 1 Date of announcement 2023/05/31 Time of announcement 23:56:02 Subject Oneness submitted an IND to US FDA for a phase II clinical trial on the broad-spectrum anti-SARS-CoV-2 siRNA (SNS812) co-developed with Microbio (Shanghai) To which item it meets paragraph 10 Date of events 2023/05/31 Statement Product:SNS812, a broad-spectrum siRNA against...Read More